10X GENOMICS ($TXG) is expected to release its quarterly earnings data on Monday, January 12th after market close, per Finnhub. Analysts are expecting revenue of $157,535,154 and earnings of -$0.23 per share.
You can see Quiver Quantitative's $TXG stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
10X GENOMICS Insider Trading Activity
10X GENOMICS insiders have traded $TXG stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:
- ADAM TAICH (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,203 shares for an estimated $533,508.
- SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 2 sales selling 22,609 shares for an estimated $380,817.
- BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 15,769 shares for an estimated $260,572.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
10X GENOMICS Revenue
10X GENOMICS had revenues of $149M in Q3 2025. This is a decrease of -1.75% from the same period in the prior year.
You can track TXG financials on Quiver Quantitative's TXG stock page.
10X GENOMICS Hedge Fund Activity
We have seen 167 institutional investors add shares of 10X GENOMICS stock to their portfolio, and 127 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 2,554,142 shares (+88.6%) to their portfolio in Q3 2025, for an estimated $29,857,919
- WELLINGTON MANAGEMENT GROUP LLP added 2,394,355 shares (+126.6%) to their portfolio in Q3 2025, for an estimated $27,990,009
- GOLDMAN SACHS GROUP INC added 2,067,562 shares (+340.2%) to their portfolio in Q3 2025, for an estimated $24,169,799
- ARK INVESTMENT MANAGEMENT LLC removed 2,004,707 shares (-14.4%) from their portfolio in Q3 2025, for an estimated $23,435,024
- AQR CAPITAL MANAGEMENT LLC removed 1,410,809 shares (-34.1%) from their portfolio in Q3 2025, for an estimated $16,492,357
- QUANTINNO CAPITAL MANAGEMENT LP added 1,258,933 shares (+56.4%) to their portfolio in Q3 2025, for an estimated $14,716,926
- ROYAL BANK OF CANADA added 1,223,602 shares (+593.6%) to their portfolio in Q3 2025, for an estimated $14,303,907
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
10X GENOMICS Government Contracts
We have seen $9,611,032 of award payments to $TXG over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROSTHETIST, PROSTHETIST TECHNICIAN, AND PROSTHETIST ASSISTANT IN THE DEPARTMENT OF SURGICAL SERVICES AND R...: $818,603
- GENE EXPRESSION REAGENTS: $334,142
- BIOLOGICAL REAGENT MATERIAL - CHROMIUM NEXT GEM SINGLE CELL MULTIOME AND GEM-X SINGLE CELL 5 KITS AND RELAT...: $249,991
- REAGENTS FOR ONGOING NGS PROJECTS (AMBIS 2270566): $249,963
- IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - KITS AND REAGENTS USED IN SINGLE-CELL AND GENE PANEL ANALYSES: $249,934
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
10X GENOMICS Analyst Ratings
Wall Street analysts have issued reports on $TXG in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 12/22/2025
- Barclays issued a "Overweight" rating on 11/07/2025
- Scotiabank issued a "Sector Outperform" rating on 10/23/2025
To track analyst ratings and price targets for 10X GENOMICS, check out Quiver Quantitative's $TXG forecast page.
10X GENOMICS Price Targets
Multiple analysts have issued price targets for $TXG recently. We have seen 9 analysts offer price targets for $TXG in the last 6 months, with a median target of $19.0.
Here are some recent targets:
- Dan Brennan from TD Cowen set a target price of $18.0 on 01/07/2026
- Kyle Mikson from Canaccord Genuity set a target price of $20.0 on 12/22/2025
- Luke Sergott from Barclays set a target price of $22.0 on 12/15/2025
- Patrick Donnelly from Citigroup set a target price of $18.0 on 12/11/2025
- Tejas Savant from Morgan Stanley set a target price of $20.0 on 12/02/2025
- David Westenberg from Piper Sandler set a target price of $19.0 on 11/11/2025
- Dan Leonard from UBS set a target price of $14.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
